The "vitalizing-2" for the prevention of atherosclerosis, cardiovascular disease and maintenance therapy of viral diseases

 

The invention relates to medicine, namely to create drugs with complex medical and preventive action, and for the composition for the prevention of atherosclerosis, cardiovascular disease and maintenance therapy of viral diseases. The invention lies in the fact that the proposed composition consists of rutin or quercetin and lysine ascorbate. Additionally, this composition may contain L-lysine monohydrochloride. Made this composition in the form of capsules. The invention provides a composition, possessing a wide spectrum of pharmacological actions without showing any side effects. 2 C. p. F.-ly, 3 tables.

The invention relates to medicine, namely to create drugs with complex medical-preventive effect.

It is known that to prevent heart disease, you can take enough antioxidants (like vitamins C and E), minerals and trace elements. It is also known that both mono-and Paliastomi containing vitamins a and C, have a beneficial effect with all viral infections, especially when used at the initial stages of the disease.

Known biological is giving MOH 001539.And.840.03.2000. This composition is manufactured in the form of tablets contains 500 mg of ascorbic acid (vitamin C). The drug is recommended as a tonic for the prevention of cardiovascular disease and as an additional source of vitamin C. the Recommended dose for adults: preventive - 2-6 tablets per day, therapeutic - 6-12 tablets per day.

The disadvantage of this structure is the high amount of ascorbic acid, high doses which cause side effects: nausea, vomiting, diarrhea, headache, fatigue, burning in the heart, hot flashes, insomnia, formation of kidney stones (crystalluria), especially in individuals with chronic renal insufficiency, phlebitis. When using such high doses, possible teratogenic effects.

Ascorbic acid in large quantities binds zinc ions and copper enhances iron absorption, reduces the content of vitamin b12affect prothrombin time (decrease) while taking oral anticoagulants. There is evidence that it can lead to an increase in deaths due to thrombophlebitis; to strengthen crystalluria, caused by aspirin, reduce the reabsorption antidepressants in the urine, ethinyl estradiol, occult blood. With decreasing concentration of bilirubin in the serum under the influence of ascorbic acid may be masked existing liver disease ("drug safety", Express-information, bul., 2000, 4, S. 15).

The present invention is the creation of a composition, possessing a wide spectrum of pharmacological actions without showing any side effects of its constituent ingredients and designed for different age groups.

This task is solved in that the proposed composition for the prevention of atherosclerosis, cardiovascular disease and maintenance therapy of viral diseases, consisting of rutin or quercetin, lysine ascorbate in the following ratio, wt.%: rutin or quercetin - 20-30 ascorbate, lysine - rest in Addition, the composition may contain L-lysine monohydrochloride in the amount of 8-12 wt.% and to be made in the form of capsules.

The proposed structure is named "Vitality-2".

The flavonoid quercetin is part of almost all vegetables, medicinal plants, fruits, berries, etc. Is the main constituent of many flavonoids, including citrus flavonoids, rutin, hesperidin, kuorikoski active substances (rutin, catechin, quercetin, citrine, and others ) in interaction with vitamin C reduce the permeability and increase capillary strength.

Lysine is an indispensable primary aliphatic amino acid. L-lysine reduces the triglycerides in the serum. Contained in avocados, peanuts, beef, pork, fish, shrimp, cheese, etc.

The above components are widely used in clinical practice when gastric ulcer and 12 duodenal ulcer, arteriosclerosis, rheumatism, strengthen the immune system and so on (Pilate T. L. et al. "Biologically active food Supplement", M, 2002).

The composition is prepared by mixing the components with subsequent kapsulirovaniem in the form of powders or granules.

The experiments were carried out on white mice or rats.

1. Acute toxicity.

Dose Vitalizing were selected based on data from literature and optimum therapeutic outcomes identified in the preliminary experiments (ascorbic acid 0.7 to 1.5 mg/kg/day, routine 0.3-0.6 mg/kg/day and L-lysine to 0.6-1.1 mg/kg/day). The weight of the mixture ranged from 1.6 to 3.2 mg/kg/day.

White mice-males weighing 20,02.0 g (n=50) did not respond to a single oral administration of the composition in the range of doses from 100 to 5000 mg/K is p>

Receiving Vitalizing with food white mice-males with an initial body weight of 20.02.0 g in doses of 10 (n=10) and 100 (n=10) times the maximum preventative (control group n=10), within 60 days did not cause the death of animals, changes in behavior, motor activity, motor coordination, reflexes status, appetite, volume of water taken and appearance.

Thus, Vitality does not have a cumulative effect.

3. Chronic toxicity.

White outbred rats with an initial weight 140,84.5 g each in the diet was added Vitality at doses of 3.2; 32,0 and 320 mg/kg/day.

Take into account the General condition of the animals, body weight, hematological parameters, morbidity and mortality. It is established that Vitality in potential prophylactic dose of 3.2 mg/kg/day and up to 100 times higher dose did not change the behavior of rats, appetite, and General condition. When this was recorded a weight gain of animals fed Vitality.

In the control group for 60 days experience weight increased by 32%. In the group treated with Vitality at a dose of 3.2 mg/kg weight gain was 43.8% in the group treated with Vitality at a dose of 32.0 mg/kg, and 39% in the group treated with Vitality at a dose of 320 mg is intellego influence on the organism and the death of animals and compared with control, by the end of the observation causes weight gain in average by 7%.

At the end of the observation period 60-day assessed the condition of the main hematological parameters of blood of animals (table 2), which is not actually changed as a result of receiving Vitalizing.

4. Evaluation of the hypolipidemic action.

Hyperlipidemia in rats-males with a mass of 150,6.2 g induced single orally administered ethanol (9 g/kg body weight) in the form of a 30-40% solution. The studied group of animals received Vitality within 10 days, and the day of the introduction of ethanol for 20-30 minutes before its introduction. After 6 hours the animals were killed and determined the cholesterol in the serum (table 3).

The introduction of ethanol in the stomach at a dose of 9 g/kg of body weight of the rats was accompanied by increased levels of serum cholesterol compared to the control at 28%, the preliminary introduction of Vitalizing at a dose of 1.6 mg/g resulting in reduced cholesterol levels by 7%, while at a dose of 3.2 mg/kg at 12%.

Thus, the proposed composition of Vitality non-toxic, has a hypolipidemic action, reduces cholesterol level in blood, has no cumulative properties.

Vitality has no contraindications.

Pre the ez protein, the absorption of carbohydrates and negative influence on the formation of atherosclerotic plaques.

Vitality can be used: - for the prevention of atherosclerosis and reduce the permeability of the vascular walls, to increase the activity of the immune system after transferring infectious diseases, to improve the absorption of calcium and the prevention of osteoporosis and for the prevention and treatment of influenza and herpes, including genital - to strengthen and build muscle, improve its elasticity and strength in sports, to improve memory,
- improve sexual function,
as an additional treatment of the cardiovascular system.

In the absence of other medical advice be taken during a meal adults - 1 capsule 2 times per day, children up to 12 years - 1 capsule per day. During increased physical activity, infectious diseases, the dose can be increased 2-3 times.

The proposed structure can be used in the form of dietary supplements as a result of the replacement of the lack of components to reduce the risk of cardiovascular and viral diseases.

Experimental and clinical data (on human volunteers) confirm that the proposed structure in this if the Formula inventions

1. Composition for the prevention of atherosclerosis, cardiovascular disease and maintenance therapy of viral diseases, characterized in that it contains rutin or quercetin and lysine ascorbate in the following ratio, wt.%:

Rutin or quercetin 20-30

Ascorbate, lysine Else

2. Composition under item 1, characterized in that it additionally contains L-lysine monohydrochloride in the amount of 8-12 wt.%.

3. Composition under item 1 or 2, characterized in that it is made in the form of capsules.

 

Same patents:

The invention relates to 5-[4-(6-methoxy-1-methyl-1H-benzimidazole-2-ylethoxy)benzyl] thiazolidin-2,4-dione hydrochloride

The invention relates to new orthotamine benzoylpyridine formula (1), where R(1) - H, alkyl with 1-8 C-atoms, Xand-(CH2)b-(CF2)c-CF3where a, b, C = 0; one of the two substituents R(2) and R(3) means-O-CO-R(27), respectively, and the other substituents R(2) and R(3) is R(1) where R(27) - alkyl with 1-8 C-atoms; R(4) is hydrogen, alkoxy with 1-4 C-atoms, F, Cl, Br, I; R(5) is hydrogen, and their pharmaceutically acceptable salts

The invention relates to medicine, namely to homeopathic, treatment and prevention tools for internal and external use, has tonic, anti-inflammatory, wound healing, detoxifying, anti-microbial, antianginal, anti-atherosclerotic, antioxidant, antihypoxic, neuroprotective, sedative, cardioprotective, anti-arrhythmic, angioprotective, stress-protective, immunotropic, antifungal, nephroprotective, hepatoprotective, gastroprotective, thermoprotector, lipoic, megaproducer, radioprotective, and retinoprotective anticoordination action

The invention relates to the field of medicine and relates to an infusion solution for improving cerebral circulation

The invention relates to novel ortho-substituted benzoylpyridine formula (1), where R(1) denotes H, halogen, Xand-(CH2)b-(CF2)with-CF3, a, b, C denote the zero, one of the two substituents R(2) and R(3) denotes hydroxyl, and the other of the substituents R(2) and R(3) is R(1), R(4) denotes a1-C4-alkyl, halogen, (CH2)n-(CF2)o-CF3n, mean zero, and their pharmaceutically acceptable salts
The invention relates to medicine, namely to intensive cardiology, and for the treatment of myocardial infarction

The invention relates to the field of medicine

The invention relates to new compounds of the mixture of isomers of 2-monoethanolamine-5(6)-nitro-1-(titanyl-3)benzimidazole of the formula I

The invention relates to medicine and concerns extract of Zanthoxylum bungeanum, obtained by extraction of its pericarp supercritical CO2analgesic activity of the extract used in the treatment of itching

The invention relates to 2-substituted 4,5-dailyedition General formula (I), where R1- 4-pyridyl; R2- phenyl, naphthas-1-yl or naphthas-2-yl, which optionally can contain up to 5 substituents selected from halogen; R3is hydrogen; R4- pyridyl, optionally substituted with halogen or amino group

The invention relates to medicine, namely to homeopathic, treatment and prevention tools for internal and external use, has tonic, anti-inflammatory, wound healing, detoxifying, anti-microbial, antianginal, anti-atherosclerotic, antioxidant, antihypoxic, neuroprotective, sedative, cardioprotective, anti-arrhythmic, angioprotective, stress-protective, immunotropic, antifungal, nephroprotective, hepatoprotective, gastroprotective, thermoprotector, lipoic, megaproducer, radioprotective, and retinoprotective anticoordination action

The invention relates to medicine and can be used for pain relief

The invention relates to medicine and veterinary medicine, namely to the use of certain derivatives of aryl(or heteroaryl)asolitarynote General formula (I) and their physiologically acceptable salts in the manufacture of drugs used in the treatment of human and/or veterinary medicine for the treatment of neurogenic inflammation observed in various pathological processes, such as diabetes, asthma, cystitis, gingivitis, headache, dermatitis, rhinitis, psoriasis, inflammation of the sciatic and lumbar nerves, gastrointestinal tract, eye inflammation, etc

The invention relates to derivatives of 2-(arylvinyl)aminoimidazole formula I, where R1denotes a group of formula (A), (B) or (C), a R2, R3, R4, R5, R6and X are such as defined in the claims

The invention relates to medicine, namely to drugs with immunomodulatory, anti-inflammatory, antitumor and antioxidant effect

The invention relates to the derivatives of pyridazine General formula I, in which R1represents phenyl or pyridyloxy group which may be substituted by 1-3 substituents selected from halogen and lower alkoxygroup; R2represents a phenyl group which may be substituted at the 4th position of the lower alkoxygroup, lower alkylthiol, lower alkylsulfonyl or lower alkylsulfonyl group and in other positions 1 or 2 substituents selected from halogen atoms, lower CNS groups, lower alkylthio, lower alkylsulfonyl groups and lower alkylsulfonyl groups;3represents a hydrogen atom; a lower CNS group; halogenated lower alkyl group; a lower cycloalkyl group; phenyl, pyridyloxy or fenoxaprop, which may be substituted by 1-3 substituents selected from halogen atoms, lower alkyl groups, lower CNS groups, carboxyl groups, lower alkoxycarbonyl groups, nitro, amino, lower alkylamino and lower alkylthio; unsubstituted or substituted lower alkyl group piperidino, piperidinyl, piperazine derivatives or morpholinopropan; unsubstituted or zameshannuu lower alkylamino group piperazinylcarbonyl group; A represents a linear or branched lower alkylenes or lower alkynylamino group having 1-6 carbon atoms; or And can mean single bond when R3represents the lower cycloalkyl or halogenated lower alkyl group; X represents an oxygen atom or a sulfur atom; provided that the following combinations are excluded: R1and R2represent 4 metoksifenilny, X represents an oxygen atom, a represents a single bond, and R3represents a hydrogen atom or 2-chloraniline group; or their salts

The invention relates to the pharmaceutical industry and relates to a mixture of primary fatty acids derived from sugar-cane wax
Up!